Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797860 | 0.87 | PDE4A (0.36) | KDM4ECYP19A1PDE4APDE4BPDE4C | |
| SCHEMBL8072005 | 0.72 | PKM (0.39) | KDM4EHSD17B10GAAMEN1MAPT | |
| SCHEMBL4947198 | 0.72 | — | — | |
| SCHEMBL7687590 | 0.71 | — | — | |
| SCHEMBL121557 | 0.67 | — | — | |
| SCHEMBL5259363 | 0.67 | — | — | |
| SCHEMBL11448869 | 0.67 | — | — | |
| SCHEMBL9543479 | 0.67 | — | — | |
| SCHEMBL30249173 | 0.67 | NOTUM (0.32) | — | |
| SCHEMBL4442023 | 0.67 | HTT (0.44) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3817810-B1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-112384282-B | Process for producing pyrrolo [2,3-d ] pyrimidine compound, intermediate and use thereof | 辉瑞公司 | 2024-07-02 | — | — | CN | disclosed |
| US-12018031-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220127274-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11254684-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3817810-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | Pfizer Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112384282-A | Process for producing pyrrolo [2,3-d ] pyrimidine compound, intermediate and use thereof | 辉瑞公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20210009601-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815240-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200123159-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2020008391-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF | PFIZER INC. (US) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009601-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | TPMT, DHPS, DPYD | KDM4E 1741/4885HSD17B10 2755/4885GAA 1588/4885 |
| US-20220127274-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | TPMT, DHPS, DPYD | KDM4E 1741/4885HSD17B10 2755/4885GAA 1588/4885 |
| US-11254684-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | TPMT, DHPS, DPYD | KDM4E 1741/4885HSD17B10 2755/4885GAA 1588/4885 |
| US-12018031-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | TPMT, DHPS, DPYD | KDM4E 1741/4885HSD17B10 2755/4885GAA 1588/4885 |
| US-20200123159-A1 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF | TPMT, DHPS, DPYD | KDM4E 1741/4885HSD17B10 2755/4885GAA 1588/4885 |
| US-10815240-B2 | Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof | TPMT, DHPS, DPYD | KDM4E 1741/4885HSD17B10 2755/4885GAA 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.